Drugs / Pegylated interferon alfa
Pegylated interferon alfa
also known as
PEG · PEG-IFN · PEG-Intron(Trademark) · PEGIntron · Peglated Interferon Alfa-2B · Pegylated Interferon · pegylated-interferon alfa-2a · RO 25-8310
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00003542 | May 1998 → Apr 2004 | kidney cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00118768 | Aug 2005 → ? | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00036569 | May 2002 → Dec 2010 | diffuse intrinsic pontine glioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00027742 | May 2001 → Jun 2005 | cutaneous melanoma, ocular melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02160080 | Jan 2014 → Feb 2017 | disease related to solid organ transplantation | Hu Tsung-Hui | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT01565889 Background | Mar 2012 → Aug 2013 | HIV infectious disease, hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03105310 Background | Jan → Dec 2016 | hepatitis D virus infection | Aga Khan University | Unknown | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated interferon alfa | “Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01565889 ↗ |
| Known as | PEG | “triple therapy with Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) treatment before liver transplantation(LT)” NCT02160080 ↗1“Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01565889 ↗ |
| Known as | PEG-IFN | “pegylated-interferon alfa-2a (PEG-IFN)” NCT00003542 ↗ |
| Known as | PEG-Intron(Trademark) | “PEG-Intron(Trademark) is a form of interferon alpha combined with monomethoxy polyethylene glycol (PEG).” NCT00036569 ↗ |
| Known as | PEGIntron | “A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma” NCT00027742 ↗ |
| Known as | Peglated Interferon Alfa-2B | “A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma” NCT00027742 ↗ |
| Known as | Pegylated Interferon | “This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the...” NCT00118768 ↗ |
| Known as | pegylated-interferon alfa-2a | “pegylated-interferon alfa-2a (PEG-IFN)” NCT00003542 ↗ |
| Known as | RO 25-8310 | “Pegylated-Interferon Alpha-2A (RO 25-8310)” NCT00003542 ↗ |
| Modality | Protein / enzyme biologic | “Interferon-alpha is a cytokine” NCT00036569 ↗ |
| Route | Subcutaneous | “pegylated interferon alfa subcutaneously once weekly” NCT00027742 ↗ |